[go: up one dir, main page]

PE20190971A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
PE20190971A1
PE20190971A1 PE2018003216A PE2018003216A PE20190971A1 PE 20190971 A1 PE20190971 A1 PE 20190971A1 PE 2018003216 A PE2018003216 A PE 2018003216A PE 2018003216 A PE2018003216 A PE 2018003216A PE 20190971 A1 PE20190971 A1 PE 20190971A1
Authority
PE
Peru
Prior art keywords
rent
compounds
r45bbr
r44bbr
phenylacetamide
Prior art date
Application number
PE2018003216A
Other languages
English (en)
Inventor
Nicholas David Adams
Andrew B Benowitz
Maria Lourdes Rueda Benede
Karen Anderson Evans
David T Fosbenner
Bryan W King
Mei Li
Juan Ignacio Luengo
William Henry Miller
Alexander Joseph Reif
Stuart Paul Romeril
Stanley J Schmidt
Roger J Butlin
Kristin M Goldberg
Allan M Jordan
Christopher S Kershaw
Ali Raoof
Bohdan Waszkowycz
Original Assignee
Glaxosmithkline Ip Dev Ltd
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd, Cancer Research Tech Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20190971A1 publication Critical patent/PE20190971A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIRIDINA DE FORMULA (IVbbr) DONDE X41bbr Y X42bbr SON CADA UNO CN, METILO, FLUOR, CLORO, ENTRE OTROS; Y4bbr ES S O NH; R41bbr ES ALQUILO C1-6, ALQUILOXI C1-4, N(ALQUILO C1-4)2, ENTRE OTROS; R43bbr ES ALQUILO C1-4, FENILO, PIPERIDINILO, ENTRE OTROS; R44bbr Y R45bbr SON CADA UNO H, ALQUILO C1-6, TRIAZOLILO, ENTRE OTROS; R44bbr Y R45bbr SE TOMAN JUNTO CON EL NITROGENO AL QUE ESTAN UNIDOS Y OPCIONALMENTE DE 1 A 3 HETEROATOMOS PARA FORMAR UN HETEROCICLOALQUILO. SON COMPUESTOS PREFERIDOS: 2-{[3,5-DICIANO-6-(DIMETILAMINO)-4-ETILPIRIDIN-2-IL]SULFANIL}-2-FENILACETAMIDA; 2-((3,5-DICIANO-4-CICLOPROPIL-6-(1,4-DIAZEPAN-1-IL)PIRIDIN-2-IL)TIO)-2-FENILACETAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES SELECTIVOS DE LA ACTIVIDAD DE ADN METILTRANSFERASA-1 (DNMT1) SIENDO UTILES EN EL TRATAMIENTO DEL CANCER
PE2018003216A 2016-06-13 2017-06-13 Compuestos quimicos PE20190971A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349227P 2016-06-13 2016-06-13
US201662393256P 2016-09-12 2016-09-12
US201662412343P 2016-10-25 2016-10-25

Publications (1)

Publication Number Publication Date
PE20190971A1 true PE20190971A1 (es) 2019-07-09

Family

ID=59239935

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003216A PE20190971A1 (es) 2016-06-13 2017-06-13 Compuestos quimicos

Country Status (20)

Country Link
US (1) US10975056B2 (es)
EP (1) EP3468953B1 (es)
JP (1) JP7051829B2 (es)
KR (1) KR20190017030A (es)
CN (1) CN109563043B (es)
AU (1) AU2017283790B2 (es)
CA (2) CA3026211A1 (es)
CL (1) CL2018003577A1 (es)
CO (1) CO2018013717A2 (es)
CR (1) CR20180580A (es)
DO (1) DOP2018000273A (es)
ES (1) ES2993451T3 (es)
IL (1) IL263163B (es)
JO (1) JOP20180120A1 (es)
MA (1) MA45244A (es)
MX (1) MX391600B (es)
PE (1) PE20190971A1 (es)
PH (1) PH12018502633B1 (es)
SG (1) SG11201809559UA (es)
WO (2) WO2017216727A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2017027645A1 (en) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
CR20190168A (es) 2016-10-04 2019-05-17 Merck Sharp & Dohme Compuestos de benzo[b]tiofeno como agonistas de sting
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
EP3661498A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3774765A4 (en) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
US10793557B2 (en) 2018-04-03 2020-10-06 Merck Sharp & Dohme Corp. Sting agonist compounds
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
CN113480541B (zh) * 2019-03-07 2022-09-02 湖南化工研究院有限公司 咪唑并吡啶化合物及其中间体的制备方法
WO2022076563A1 (en) * 2020-10-07 2022-04-14 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
AU2022230795B2 (en) 2021-03-02 2025-02-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as dnmt1 inhibitors
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN113278021B (zh) * 2021-05-29 2022-09-23 天津全和诚科技有限责任公司 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
CN114230459A (zh) * 2021-12-10 2022-03-25 武汉九州钰民医药科技有限公司 一种化合物的制备方法及分析检测方法
WO2023192629A1 (en) * 2022-04-01 2023-10-05 Herophilus, Inc. Induction of mecp2 expression by dna methyl transferase inhibitors
WO2024156288A1 (en) * 2023-01-29 2024-08-02 Shanghai Kygent Pharmaceutical Co., Ltd Dnmt1 inhibitors, pharmaceutical compositions, and therapeutic applications
CN121368481A (zh) * 2023-06-29 2026-01-20 丹娜-法伯癌症研究院 用于降解dna甲基转移酶1 (dnmt1)的蛋白水解靶向嵌合体(protacs)的合成和体外表征
WO2025085756A1 (en) * 2023-10-18 2025-04-24 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
WO2025190285A1 (en) * 2024-03-12 2025-09-18 Shanghai Kygent Pharmaceutical Co., Ltd Pyridine compounds, pharmaceutical compositions, and applications
CN119306700A (zh) * 2024-08-28 2025-01-14 山东大学 Dnmt1-hdac双靶点抑制剂及其制备方法和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030875C (en) 1990-11-26 2002-07-02 Alan R.P. Paterson Methods and probes for detecting nucleoside transporter and method for producing the probes
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
ZA942125B (en) 1993-03-26 1994-11-10 Shell Res Ltd Herbicidal heterocyclic compounds.
CN1209063A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
BR9612378A (pt) 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores de vitronectina
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
AU2108601A (en) 1999-12-15 2001-06-25 Axys Pharmaceuticals, Inc. Salicylamides as serine protease inhibitors
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
US20030166554A1 (en) 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
TW200406370A (en) 2002-06-28 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives
TW200406152A (en) 2002-08-30 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy) phenol derivatives having pesticidal properties
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
TW200410632A (en) 2002-12-11 2004-07-01 Syngenta Participations Ag Dihalo-allyloxy-phenol derivatives having pesticidal activity
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
EP1610774A4 (en) 2003-04-09 2008-07-16 Exelixis Inc TIE-2 MODULATORS AND METHODS OF USE
CA2526361C (en) 2003-05-20 2012-05-15 Ajinomoto Co., Inc. Amide derivative
CN1856307A (zh) 2003-09-23 2006-11-01 默克公司 喹啉钾通道抑制剂
AU2011253934C1 (en) 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1655296A1 (en) 2004-10-25 2006-05-10 Graffinity Pharmaceuticals AG Thrombin inhibitors
EP1844062A2 (en) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibitors of dna methyltransferase
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
AU2007262055A1 (en) 2006-06-20 2007-12-27 Ishihara Sangyo Kaisha, Ltd. Pest control agent containing novel pyridyl-methanamine derivative or salt thereof
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
WO2008093075A2 (en) 2007-02-01 2008-08-07 Astrazeneca Ab 5,6,7,8-tetrahydropteridine derivatives as hsp90 inhibitors
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009034433A2 (en) 2007-09-10 2009-03-19 Glenmark Pharmaceuticals, S.A. 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
EP2195304B1 (en) 2007-10-08 2014-01-08 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
WO2010007756A1 (ja) * 2008-07-14 2010-01-21 塩野義製薬株式会社 Ｔｔｋ阻害作用を有するピリジン誘導体
WO2010020810A1 (en) 2008-08-19 2010-02-25 Astrazeneca Ab 2-(imidaz0lylamin0)-pyridine derivatives and their use as jak kinase inhibitors
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
KR101146010B1 (ko) * 2009-09-10 2012-05-16 서울대학교산학협력단 ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물
CN102686584A (zh) 2009-11-13 2012-09-19 盐野义制药株式会社 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物
US8440689B2 (en) 2009-12-23 2013-05-14 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones
JP5793505B2 (ja) 2009-12-23 2015-10-14 ジャスコ ファーマシューティカルズ， エルエルシー アミノピリミジンキナーゼ阻害薬
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
WO2011103289A2 (en) 2010-02-17 2011-08-25 Jasco Pharmaceuticals, LLC Imidazole-2, 4-dione inhibitors of casein kinase 1
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
US9422262B2 (en) 2010-09-24 2016-08-23 The Broad Institute, Inc. Compounds and methods for treating diseases mediated by protease activated receptors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CA2824808A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013019621A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2747560A4 (en) 2011-07-29 2015-02-25 Tempero Pharmaceuticals Inc CONNECTIONS AND METHODS
EP2771012A4 (en) * 2011-10-24 2015-06-24 Glaxosmithkline Ip No 2 Ltd NEW CONNECTIONS
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
US9914730B2 (en) 2012-09-28 2018-03-13 Cancer Research Technology Limited Azaquinazoline inhibitors of Atypical protein Kinase C
JP2017502968A (ja) 2014-01-21 2017-01-26 ウォックハート リミテッド ７−オキソ−１，６−ジアザビシクロ［３．２．１］オクタン誘導体及び抗菌剤としてのその使用
WO2015110999A1 (en) 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof

Also Published As

Publication number Publication date
JOP20180120A1 (ar) 2019-01-30
EP3468953A1 (en) 2019-04-17
WO2017216726A1 (en) 2017-12-21
MX2018015483A (es) 2019-03-18
CA3026211A1 (en) 2017-12-21
SG11201809559UA (en) 2018-12-28
IL263163B (en) 2021-10-31
CN109563043B (zh) 2022-05-31
JP2019517596A (ja) 2019-06-24
CR20180580A (es) 2019-07-02
CA3026226A1 (en) 2017-12-21
MA45244A (fr) 2019-04-17
EP3468953C0 (en) 2024-05-22
US20190194166A1 (en) 2019-06-27
ES2993451T3 (en) 2024-12-30
KR20190017030A (ko) 2019-02-19
CN109563043A (zh) 2019-04-02
EP3468953B1 (en) 2024-05-22
AU2017283790B2 (en) 2019-08-29
JP7051829B2 (ja) 2022-04-11
BR112018075992A2 (pt) 2019-04-02
PH12018502633A1 (en) 2019-09-30
CO2018013717A2 (es) 2019-01-18
CL2018003577A1 (es) 2019-04-05
PH12018502633B1 (en) 2023-02-01
IL263163A (en) 2018-12-31
US10975056B2 (en) 2021-04-13
AU2017283790A1 (en) 2018-11-22
WO2017216727A1 (en) 2017-12-21
MX391600B (es) 2025-03-21
DOP2018000273A (es) 2019-03-31

Similar Documents

Publication Publication Date Title
PE20190971A1 (es) Compuestos quimicos
BR112017000550A2 (pt) compostos antiproliferativos e métodos de uso dos mesmos
CY1121334T1 (el) Αναστολεας κινασης aurora a
PE20161573A1 (es) Ciclopropilamina como inhibidor de la lsd1
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
UY29633A1 (es) Derivados de oxindol
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
EP3313385A4 (en) AZIRID-CONTAINING DNA ALKYLATING AGENTS
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
MX2016013908A (es) Novedoso compuesto de 1,2,4-triazina disustituida.
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
PE20180355A1 (es) Desacetoxitubulisina h y analogos de esta
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز
EA201891782A1 (ru) Гетероциклическое сульфонамидное производное и содержащее его лекарственное средство
BR112018012660A2 (pt) composto, sal, composto sólido, polimorfo a, polimorfo b, polimorfo c, polimorfo d, composição, método de inibição da atividade de gls1 em uma amostra biológica, métodos de tratamento de um distúrbio mediado por gls1 em um sujeito necessitado, composto, sal, solvato ou polimorfo, e uso de um composto, sal, solvato ou polimorfo
MX389613B (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
EA201791456A1 (ru) Пептиды-антагонисты cgrp
MX387252B (es) EL USO DE DERIVADOS DE QUINOLINONAS QUE TIENE UNA ACTIVIDAD DE INHIBICIÓN DE LA FORMACIÓN DEL COMPLEJO DE C-Myc/Max/ADN EN EL TRATAMIENTO DE CANCER.
TH75083B (th) ระบบสนับสนุนงาน, เครื่องปลายทางแบบพกพา และวิธีการสนับสนุนงาน
CY1116368T1 (el) Συνθεσεις για χρηση στη θεραπεια ιογενων λοιμωξεων
TH182770A (th) ตัวยับยั้งแอลโดสเทอโรน ซินเธส
TH182729A (th) อนุพันธ์ฟีนอกซีเมทธิล